ORAMED PHARMACEUTICALS INC. Deferred Revenue
ORAMED PHARMACEUTICALS INC. (ORMP) had Deferred Revenue of $674.00 thousand as of 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Balance Sheet › Liabilities
us-gaap:DeferredRevenue · last filed 2023-05-11
- 2023-03-31: Deferred Revenue $674.00K.
- 2022-12-31: Deferred Revenue $1.34M.
- 2022-09-30: Deferred Revenue $2.02M.
- 2022-06-30: Deferred Revenue $2.70M.
| Period end | Deferred Revenue | Deferred Revenue as first filed |
|---|---|---|
| 2023-03-31 | $674.00K 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $1.34M 10-Q · filed 2023-05-11 | |
| 2022-09-30 | $2.02M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $2.70M 10-Q · filed 2022-08-10 | |
| 2022-03-31 | $2.70M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $2.70M 10-K · filed 2023-03-06 | |
| 2021-11-30 | $2.70M 10-Q · filed 2022-01-11 | |
| 2021-08-31 | $2.70M 10-QT · filed 2022-03-30 | |
| 2020-08-31 | $2.70M 10-K · filed 2021-11-24 | |
| 2019-08-31 | $12.36M 10-K · filed 2019-11-27 | |
| 2018-08-31 | $13.84M 10-K · filed 2019-11-27 | |
| 2018-05-31 | $700.00K 10-K · filed 2018-11-28 | $14.45M 10-Q · filed 2018-07-12 |
| 2018-02-28 | $15.07M 10-Q · filed 2018-04-09 | |
| 2017-08-31 | $16.29M 10-K · filed 2019-11-27 | |
| 2016-08-31 | $14.77M 10-K · filed 2018-11-28 | |
| 2016-05-31 | $4.59M 10-Q · filed 2016-07-06 | |
| 2016-02-29 | $4.76M 10-Q · filed 2016-04-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |